KR100895749B1 - Nkg2d의 조절 - Google Patents
Nkg2d의 조절 Download PDFInfo
- Publication number
- KR100895749B1 KR100895749B1 KR1020087022757A KR20087022757A KR100895749B1 KR 100895749 B1 KR100895749 B1 KR 100895749B1 KR 1020087022757 A KR1020087022757 A KR 1020087022757A KR 20087022757 A KR20087022757 A KR 20087022757A KR 100895749 B1 KR100895749 B1 KR 100895749B1
- Authority
- KR
- South Korea
- Prior art keywords
- nkg2d
- cells
- mice
- rae
- disease
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
Description
NKG2D 내재화의 자극 (대조군에 비교시 NKG2D 표면 수준의 감소% 또는 소실율의 증가%) | NKG2D 활성화 (NKG2D-리간드 보유 세포에 노출한 후 NKG2D-보유 세포의 활성화 감소%) | NKG2D-발현 세포의 고갈 (대조군에 비교시 NKG2D 발현 세포의 감소%) |
20% | 30% | <5% |
20 | 50 | <5 |
20 | 70 | <5 |
20 | 90 | <5 |
20 | 70 | 10 |
20 | 70 | 20 |
20 | 70 | 30 |
20 | 70 | 50 |
40 | 30 | <5 |
40 | 50 | <5 |
40 | 70 | <5 |
40 | 90 | <5 |
40 | 70 | 10 |
40 | 70 | 20 |
40 | 70 | 30 |
40 | 70 | 50 |
90 | 30 | <5 |
90 | 50 | <5 |
90 | 70 | <5 |
90 | 90 | <5 |
90 | 70 | 10 |
90 | 70 | 20 |
90 | 70 | 30 |
90 | 70 | 50 |
Claims (29)
- 다량체성 MICA, MICA의 다량체성 NKG2D-결합 단편, 다량체성 MICB, MICB의 다량체성 NKG2D-결합 단편, 다량체성 ULBP, ULBP의 다량체성 NKG2D-결합 단편, 및 서열 10, 서열 11 및 서열 12로 이루어진 군으로부터 선택되는 서열을 갖는 RNAi 분자로 이루어진 군으로부터 선택되며 NKG2D-발현 백혈구의 리간드-유도 NKG2D 활성화를 감소시키고 백혈구의 표면 상에서 NKG2D의 양을 감소시키는 작용제를 포함하며, I형 당뇨병, 류마티스성 관절염, 다발성 경화증, 복강 질환, 염증성 장질환, 건선, 전신성 홍반성 루푸스, 하시모토 갑상선염, 중증 근육무력증, 길랑 바레 (Guillain-Barre) 증후군, 자가면역 포도막염, 원발성 담즙성 간경변, 자가면역 간염, 자가면역 용혈성 빈혈, 악성 빈혈, 자가면역 저혈소판증, 그레이브스병, 자가면역 난소염, 자가면역 고환염, 측두동맥염, 항-인지질 증후군, 베게너 육아종증, 베체트 (Behcet) 병, 공피증, 다발성 근염, 피부근육염, 강직척추염, 쇼그렌 (Sjogren) 증후군, 포진피부염, 심상성 천포창, 백반증, 건선 관절염, 골관절염, 스테로이드-내성 천식, 만성 폐쇄성 폐 질환, 아테롬성 동맥경화증, 골수 이식 거부반응 및 말초 혈액 줄기세포 이식 거부반응으로 이루어진 군으로부터 선택된 질환을 치료 또는 예방하기 위한 의약.
- 제1항에 있어서, 리간드-유도 NKG2D 활성화의 감소가 NKG2D를 발현하는 백혈구를 작용제와 접촉시키는 것을 포함하는 것인 의약.
- 제1항 또는 제2항에 있어서, 상기 작용제와의 접촉에 의해 리간드-유도 NKG2D 활성화가 30% 이상 감소되는 의약.
- 제1항 또는 제2항에 있어서, 상기 작용제가 NKG2D와 DAP10의 상호작용을 감소시키는 것인 의약.
- 제1항 또는 제2항에 있어서, 상기 작용제가 세포-표면 NKG2D의 내재화 속도를 증가시키는 것인 의약.
- 제1항 또는 제2항에 있어서, 세포-표면 NKG2D의 양의 상기 감소가, 천연 가용성 MICA, MICB, ULBP1, ULBP2, ULBP3, 또는 ULBP4 중 1종 이상이 세포-표면 NKG2D의 양을 감소시킬 수 없는 조건 하에 일어나는 것인 의약.
- 제5항에 있어서, NKG2D 내재화 속도의 상기 증가가, 천연 가용성 MICA, MICB, ULBP1, ULBP2, ULBP3, 또는 ULBP4 중 1종 이상이 NKG2D의 내재화 속도를 증가시킬 수 없는 조건 하에 일어나는 것인 의약.
- 제1항 또는 제2항에 있어서, 상기 작용제와의 접촉에 의해 NKG2D-NKG2D 리간드 복합체를 통한 신호전달이 감소되는 의약.
- 제1항 또는 제2항에 있어서, 백혈구가 NKG2D+ CD8+ T 세포, NKG2D+CD4+ T 세포, NKG2D+γδ T 세포, NKG2D+ NK 세포, 및 대식세포로 이루어진 군 중에서 선택되는 것인 의약.
- 제1항 또는 제2항에 있어서, 상기 작용제가 대조군에 비해 NKG2D-발현 백혈구의 수를 10% 미만으로 감소시키는 것인 의약.
- 제1항 또는 제2항에 있어서, 상기 작용제가 NKG2D-코딩 핵산의 전사 또는 번역을 감소시키는 RNAi 분자인 의약.
- 제1항 또는 제2항에 있어서, NKG2D 리간드 발현이 상기 질환에 걸린 기관 또는 조직의 세포에서 상승되는 의약.
- 제1항 또는 제2항에 있어서, 상기 작용제가 상기 질환에 걸린 기관 또는 조직에 침윤하는 림프구를 감소시키는 것인 의약.
- 제1항 또는 제2항에 있어서, 상기 작용제가 상기 질환에 걸린 기관 또는 조직에서 인터페론-감마 수준을 감소시키는 것인 의약.
- 제1항 또는 제2항에 있어서, 상기 작용제가 상기 백혈구의 증식을 감소시키는 것인 의약.
- 제1항 또는 제2항에 있어서, 질환에 걸린 것으로 진단된 인간 환자를 치료하기 위한 의약.
- 제1항 또는 제2항에 있어서, 류마티스성 관절염을 치료 또는 예방하기 위한 의약.
- 제1항 또는 제2항에 있어서, I형 당뇨병을 치료 또는 예방하기 위한 의약.
- 제1항 또는 제2항에 있어서, 다발성 경화증을 치료 또는 예방하기 위한 의약.
- 제1항 또는 제2항에 있어서, 복강 질환을 치료 또는 예방하기 위한 의약.
- 제1항 또는 제2항에 있어서, 염증성 장질환을 치료 또는 예방하기 위한 의약.
- 제1항 또는 제2항에 있어서, 전신성 홍반성 루푸스를 치료 또는 예방하기 위 한 의약.
- 제1항 또는 제2항에 있어서, 골수 이식 거부반응을 치료 또는 예방하기 위한 의약.
- 다량체성 MICA, MICA의 다량체성 NKG2D-결합 단편, 다량체성 MICB, MICB의 다량체성 NKG2D-결합 단편, 다량체성 ULBP, ULBP의 다량체성 NKG2D-결합 단편, 및 서열 10, 서열 11 및 서열 12로 이루어진 군으로부터 선택되는 서열을 갖는 RNAi 분자로 이루어진 군으로부터 선택되는 NKG2D 조절자; 및 I형 당뇨병, 류마티스성 관절염, 다발성 경화증, 복강 질환, 염증성 장질환, 건선, 전신성 홍반성 루푸스, 하시모토 갑상선염, 중증 근육무력증, 길랑 바레 (Guillain-Barre) 증후군, 자가면역 포도막염, 원발성 담즙성 간경변, 자가면역 간염, 자가면역 용혈성 빈혈, 악성 빈혈, 자가면역 저혈소판증, 그레이브스병, 자가면역 난소염, 자가면역 고환염, 측두동맥염, 항-인지질 증후군, 베게너 육아종증, 베체트 (Behcet) 병, 공피증, 다발성 근염, 피부근육염, 강직척추염, 쇼그렌 (Sjogren) 증후군, 포진피부염, 심상성 천포창, 백반증, 건선 관절염, 골관절염, 스테로이드-내성 천식, 만성 폐쇄성 폐 질환, 아테롬성 동맥경화증, 골수 이식 거부반응 및 말초 혈액 줄기세포 이식 거부반응으로 이루어진 군으로부터 선택된 질환의 치료 또는 예방을 위하여 백혈구를 상기 NKG2D 조절자와 접촉시키기 위한 지시서를 포함하는, 상기 질환의 치료 또는 예방용 키트.
- 제24항에 있어서, 상기 백혈구가 인간 백혈구이고, 상기 지시서가 질환에 걸린 것으로 진단된 인간 환자의 치료용인 키트.
- 제24항 또는 제25항에 있어서, NKG2D 조절자가 백혈구의 표면 상에서 NKG2D의 양을 감소시키는 것인 키트.
- i) NKG2D+ 백혈구를 시험 조절제와 접촉시키고;ii) 상기 백혈구에 의한 NKG2D 발현을 측정하거나, 상기 백혈구에 의한 리간드-유도 NKG2D 활성화를 측정하는 것을 포함하는, 다량체성 MICA, MICA의 다량체성 NKG2D-결합 단편, 다량체성 MICB, MICB의 다량체성 NKG2D-결합 단편, 다량체성 ULBP, ULBP의 다량체성 NKG2D-결합 단편, 및 서열 10, 서열 11 및 서열 12로 이루어진 군으로부터 선택되는 서열을 갖는 RNAi 분자로 이루어진 군으로부터 선택되는 NKG2D 조절제의 확인 방법.
- 제27항에 있어서, NKG2D 발현의 측정이 NKG2D 전사, 번역, 및 내재화를 측정하는 것 중 하나 이상을 포함하는 것인 방법.
- 제27항에 있어서, 리간드-유도 NKG2D 활성화의 측정이 DAP10 포스포릴화, p85 PI3 키나제 활성, Akt 키나제 활성, IFN-γ의 생산, 및 NKG2D 리간드+ 표적 세포의 세포용해를 측정하는 것 중 하나 이상을 포함하는 것인 방법.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55991904P | 2004-04-05 | 2004-04-05 | |
US60/559,919 | 2004-04-05 | ||
US57624204P | 2004-06-01 | 2004-06-01 | |
US60/576,242 | 2004-06-01 | ||
US65967805P | 2005-03-07 | 2005-03-07 | |
US60/659,678 | 2005-03-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067023094A Division KR100912994B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080089677A KR20080089677A (ko) | 2008-10-07 |
KR100895749B1 true KR100895749B1 (ko) | 2009-04-30 |
Family
ID=35125614
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097008488A KR100919915B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
KR1020067023094A KR100912994B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
KR1020087022757A KR100895749B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097008488A KR100919915B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
KR1020067023094A KR100912994B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20080260727A1 (ko) |
EP (3) | EP2289534B1 (ko) |
JP (2) | JP4667451B2 (ko) |
KR (3) | KR100919915B1 (ko) |
CN (2) | CN1984672B (ko) |
AT (1) | ATE435656T1 (ko) |
AU (2) | AU2005231478C1 (ko) |
BR (1) | BRPI0509620A (ko) |
CA (1) | CA2563313C (ko) |
DE (1) | DE602005015302D1 (ko) |
DK (1) | DK1732588T3 (ko) |
ES (2) | ES2328597T3 (ko) |
MX (1) | MXPA06011553A (ko) |
PL (1) | PL1732588T3 (ko) |
WO (1) | WO2005097160A2 (ko) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7998481B2 (en) * | 2004-04-05 | 2011-08-16 | The Regents Of The University Of California | Modulation of NKG2D for treating or preventing solid organ allograft rejection |
WO2005115517A2 (en) * | 2004-04-28 | 2005-12-08 | Joslin Diabetes Center, Inc. | Methods of treating diabetes |
US20070248607A1 (en) * | 2005-11-03 | 2007-10-25 | Thomas Spies | Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells |
WO2008014035A2 (en) * | 2006-07-25 | 2008-01-31 | The Regents Of The University Of California | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection |
CN105001333B (zh) * | 2007-12-14 | 2019-05-17 | 诺沃—诺迪斯克有限公司 | 抗人nkg2d抗体及其用途 |
ES2550384T3 (es) | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
RU2566264C2 (ru) * | 2009-08-17 | 2015-10-20 | Дзе Пенн Стейт Рисерч Фаундейшн | Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа |
EP2621514B1 (en) | 2010-09-28 | 2016-09-21 | KAHR Medical (2005) Ltd | Compositions and methods for treatment of hematological malignancies |
KR101240206B1 (ko) | 2010-10-05 | 2013-03-06 | 고려대학교 산학협력단 | 자연살상 세포-매개 면역반응 억제용 조성물 |
EP2747785A4 (en) * | 2011-08-26 | 2015-04-15 | Univ California | METHOD AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES THROUGH NKG2D INHIBITION |
EP3628329B1 (en) * | 2011-09-30 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica) |
GB201218195D0 (en) * | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
KR102228828B1 (ko) * | 2014-03-11 | 2021-03-16 | 셀렉티스 | 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법 |
BR112017018224A2 (pt) * | 2015-03-11 | 2018-04-17 | Cellectis | métodos para manipulação de célula t alogênica para aumentar sua persistência e/ou implante em pacientes |
EP4006146B1 (en) * | 2015-09-03 | 2023-09-06 | The UAB Research Foundation | Genetically-engineered drug resistant t cells and methods of using the same |
EP3373952A4 (en) | 2015-11-10 | 2019-05-22 | Fred Hutchinson Cancer Research Center | NKG2D decoys |
CN114853907A (zh) | 2015-11-13 | 2022-08-05 | 达纳-法伯癌症研究所有限公司 | 用于癌症免疫疗法的nkg2d-ig融合蛋白 |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
WO2018175390A1 (en) * | 2017-03-20 | 2018-09-27 | Washington University | Cells and methods of uses and making the same |
JP2021505207A (ja) * | 2017-12-05 | 2021-02-18 | セリアド エス.アー.Celyad S.A. | Nkg2dベースの受容体を発現する免疫細胞のフラトリサイドの減少 |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
CN110713977B (zh) * | 2018-07-12 | 2022-05-27 | 上海赛傲生物技术有限公司 | 一种cd8 t细胞的培养扩增方法 |
WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
EP3935159A1 (en) | 2019-03-08 | 2022-01-12 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
KR20220044266A (ko) | 2019-06-12 | 2022-04-07 | 옵시디안 테라퓨틱스, 인크. | 조정 가능한 조절을 위한 ca2 조성물 및 방법 |
US20220267398A1 (en) | 2019-06-12 | 2022-08-25 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
US20220323541A1 (en) * | 2019-08-13 | 2022-10-13 | Courier Therapeutics, Inc. | Orthopoxvirus major histocompatibility complex (mhc) class-i like protein (omcp) for treatment of autoimmune disease |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA89189A (en) | 1904-03-10 | 1904-09-13 | Frederick Palm | Valve |
CA95137A (en) | 1905-07-25 | 1905-09-19 | William E. Hingston | Envelope |
DK26743C (da) | 1918-10-14 | 1920-10-04 | Fabrikanter Og Forhandlere Af | Symaskine. |
DK63720C (da) | 1944-02-26 | 1945-07-23 | Jes Hansen Lauritzen | Anordning ved Maksimalafbrydere med en alt efter Overbelastningens Størrelse forsinket eller øjeblikkelig Afbrydelse af Forbrugsstrømmen. |
US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
JPH06506358A (ja) | 1991-03-28 | 1994-07-21 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | ナチュラルキラー細胞に特異的なdnaおよびアミノ酸配列 |
US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
US5789244A (en) | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
WO1998019167A2 (en) | 1996-10-29 | 1998-05-07 | Fred Hutchinson Cancer Research Center, Inc. | Cell stress regulated human mhc class i gene |
HUP0001964A3 (en) | 1997-01-29 | 2002-01-28 | Cornell Res Foundation Inc Ith | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
IL136621A0 (en) * | 1997-12-17 | 2001-06-14 | Immunex Corp | Cell surface glycoproteins associated with human b cell lymphomas |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
US6414218B1 (en) | 2000-01-18 | 2002-07-02 | The General Hospital Corporation | Mouse model for rheumatoid arthritis |
WO2001077350A2 (en) | 2000-04-07 | 2001-10-18 | Large Scale Biology Corporation | Compositions and methods for inhibiting gene expression |
US20040031066A9 (en) | 2001-01-18 | 2004-02-12 | Faustman Denise L. | Mouse model for rheumatoid arthritis |
US20040115198A1 (en) | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
US20030095965A1 (en) * | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
US6821522B2 (en) * | 2001-05-31 | 2004-11-23 | The Regents Of The University Of California | Tumor Therapy |
US20030171280A1 (en) * | 2001-07-31 | 2003-09-11 | Soderstrom Karl Petter | Compositions and methods for modulation of immune responses |
WO2003089616A2 (en) * | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
US7666417B2 (en) * | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
US7998481B2 (en) * | 2004-04-05 | 2011-08-16 | The Regents Of The University Of California | Modulation of NKG2D for treating or preventing solid organ allograft rejection |
-
2005
- 2005-04-05 DK DK05761976T patent/DK1732588T3/da active
- 2005-04-05 AU AU2005231478A patent/AU2005231478C1/en not_active Ceased
- 2005-04-05 AT AT05761976T patent/ATE435656T1/de not_active IP Right Cessation
- 2005-04-05 EP EP10183329.1A patent/EP2289534B1/en not_active Not-in-force
- 2005-04-05 BR BRPI0509620-0A patent/BRPI0509620A/pt not_active Application Discontinuation
- 2005-04-05 MX MXPA06011553A patent/MXPA06011553A/es active IP Right Grant
- 2005-04-05 US US11/547,878 patent/US20080260727A1/en not_active Abandoned
- 2005-04-05 EP EP09008665.3A patent/EP2248529B1/en not_active Not-in-force
- 2005-04-05 CN CN2005800179326A patent/CN1984672B/zh not_active Expired - Fee Related
- 2005-04-05 ES ES05761976T patent/ES2328597T3/es active Active
- 2005-04-05 KR KR1020097008488A patent/KR100919915B1/ko active IP Right Grant
- 2005-04-05 EP EP05761976A patent/EP1732588B1/en active Active
- 2005-04-05 KR KR1020067023094A patent/KR100912994B1/ko active IP Right Grant
- 2005-04-05 KR KR1020087022757A patent/KR100895749B1/ko active IP Right Grant
- 2005-04-05 DE DE602005015302T patent/DE602005015302D1/de active Active
- 2005-04-05 ES ES10183329.1T patent/ES2645026T3/es active Active
- 2005-04-05 WO PCT/US2005/011487 patent/WO2005097160A2/en active Application Filing
- 2005-04-05 CN CN201210340116.0A patent/CN102988959B/zh not_active Expired - Fee Related
- 2005-04-05 PL PL05761976T patent/PL1732588T3/pl unknown
- 2005-04-05 JP JP2007507429A patent/JP4667451B2/ja not_active Expired - Fee Related
- 2005-04-05 CA CA2563313A patent/CA2563313C/en not_active Expired - Fee Related
-
2009
- 2009-01-23 AU AU2009200269A patent/AU2009200269B2/en not_active Ceased
-
2010
- 2010-10-06 JP JP2010226316A patent/JP5693127B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-25 US US15/081,305 patent/US20160311906A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
Immunity, Vol.18, No.1, pp41-51 (2003.1.) |
J. Exp. Med., Vol.197, No.10, pp1245-253 (2003.5.) |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100895749B1 (ko) | Nkg2d의 조절 | |
US7998481B2 (en) | Modulation of NKG2D for treating or preventing solid organ allograft rejection | |
JP5936818B2 (ja) | 細胞傷害活性抗lag−3モノクローナル抗体および臓器移植拒絶および自己免疫疾患の治療または予防における該抗体の使用方法 | |
WO2008014035A2 (en) | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection | |
KR20230006477A (ko) | Hsp70을 표적화하는 모노클로날 항체 및 이의 치료학적 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130409 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140408 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160408 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170412 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180412 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190410 Year of fee payment: 11 |